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Donor-strain-derived immature dendritic cell pre-treatment induced
hyporesponsiveness against allogeneic antigens
Introduction
Over the last four decades there has been a marked
improvement in the short-term survival of allografts;
however, long-term graft survival has remained relatively
unchanged.1,2 The discovery of a variety of potent immuno-
suppressive agents capable of preventing acute graft rejec-
tion, has been less effective against chronic graft loss.
Most allograft recipients suffer from toxicities and com-
plications associated with the use of immunosuppressive
agents, ranging from susceptibility to opportunistic infec-
tion, to fatal malignancies. The induction of donor-
specific allograft tolerance has increasingly demanded
the need for a more definitive goal for the scientists
working in this field to address.
Dendritic cells (DCs) are specialized antigen-presenting
cells (APCs) that are unique in their capacity to present
antigens for the activation of naı̈ve T cells.3 The induction
of an appropriate immune response via T cells depends
on DC-mediated antigen presentation. When DCs
encounter antigens along with the appropriate signals,
they begin to mature and express costimulatory mole-
cules, hence triggering an immune response.4–6 Recent
studies have demonstrated that DCs play a critical role in
the regulation of the immune reaction, possibly by influ-
encing the spatial proximity between regulatory T cells
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Summary
The maturation of antigen-presenting dendritic cells (DCs) serves as an
important determinant for the regulation of immunity, and overall
immune response. We hypothesized that a reduced immune response to
donor alloantigens and improved allograft survival could be induced by
pre-treating recipients with bone-marrow-derived donor-strain fixed
immature DCs (FIDCs). Donor-strain-derived mature and immature DCs
were fixed before grafting to ensure that they possessed a stable immuno-
genic phenotype. The fixed mature DCs effectively induced allogeneic
T-cell proliferation in recipients, whereas FIDCs were unable to elicit an
allogeneic T-cell response. T cells that had previously been exposed to
FIDCs maintained naı̈ve phenotypes and were unable to extensively divide
after injection into lethally irradiated donor-strain mice. The pre-treat-
ment of recipients with donor-strain FIDCs markedly prolonged the sur-
vival of islet as well as skin allografts. However, T-cell hyporesponsiveness
induced by FIDC injection was abrogated by the depletion of CD4+
CD25+ T cells. Consequently, FIDC-induced T-cell hyporesponsiveness
could reflect anergy rather than specific deletion. Our findings suggest
that FIDCs of donor strain could be used to induce long-term graft sur-
vival.
Keywords: clonal hyporeactivity; dendritic cells; long-term graft survival;
maturation; tolerance
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and effector T cells, and/or expressing regulatory
cytokines.7 Dendritic cells are capable of simultaneously
presenting antigens to regulatory T cells and effector T
cells, thereby bringing two classes of T cells into spatial
proximity and facilitating ‘linked suppression’.8 Since the
discovery of the immature DCs that were able to induce a
state of hyporesponsiveness in T cells, the phenomenon
has been used for the control or suppression of the
immune response. In the fields of transplantation and
autoimmune immunology, numerous attempts have been
made to modify DCs to retain their immature phenotype
for the induction of antigen-specific tolerance. To induce
hyporesponsiveness in murine allograft models, various
subtypes of DCs with an immature phenotype have been
investigated.9–11 However, previous studies have shown
inconsistent results, possibly because of the spontaneous
maturation of DCs in vivo, and the subsequent activation
of an immune response.12,13 The physical and biochemical
properties of DCs perform crucial roles in dictating
whether the elicited immune response is stimulatory or
inhibitory. Several attempts have been made to render
DCs maturation-resistant; however, only fixation of the
plasma membrane has resulted in the abrogation of DC-
induced T-cell proliferation. Although conflicting evi-
dence exists, the type of APC used and the maturation
status of DCs at the time of fixation are the primary fac-
tors that determine the induced alloimmune response.14–16
In this study, we used paraformaldehyde fixation to
maintain and manage bone marrow (BM)-derived DCs in
an immature state. Pre-treatment with donor strain-
derived fixed immature DCs (FIDCs) was used to evalu-
ate the efficacy of antigen presentation in allogeneic
immune responses. In essence, the effects on the immune
response to allograft survival and the possible immune
mechanism of action were investigated.
Materials and methods
Animals
BALB/c (H-2d), DBA2 (H-2d), C57BL/6 (H-2b), CB6F1
(H-2b,d), C3H (H-2k) and DBA1 (H-2q) mice, aged
6–8 weeks, were purchased from Jackson Laboratories (Bar
Harbor, ME) and from the Center for Animal Resource
Development (Seoul National University, Seoul, Korea).
The TEa CD4+ T-cell receptor (TCR) transgenic mice were
kindly provided by Dr Alexander D. Rudensky (University
of Washington, Seattle). CD4+ transgenic cells express a
TCR that recognizes the peptide ASFEAQGALANIAVDKA
in the context of I-Ab. This peptide corresponds to posi-
tions 52 to 68 from the a-chain of I-E class II molecules,
and is expressed in all APCs from H-2d/I-E+ strains
(CB6F1).17 All mice were maintained in specific patho-
gen-free conditions at the Beth Israel Deaconess Medical
Center animal facility or the Laboratory for Experimental
Animal Research, the Clinical Research Institute, Seoul
National University Hospital, Seoul, Korea.
Antibodies and flow cytometric analysis
The following fluorescence-conjugated antibodies were
purchased from BD PharMingen (San Jose, CA); anti-
CD4, anti-CD8, anti CD11c, anti-CD25, anit-CD62L,
anti-CD40, anti-CD86, anti-GR1, anti TER119, RA3-3A1/
6.1, anti-B220/CD45R, anti-IAb and anti-Vb6 TCR mono-
clonal antibodies (mAbs). Antibodies were used for sort-
ing or staining surface molecules for analysis. Analyses
were performed using FACSCalibur and FACScan flow
cytometers (BD Biosciences, Franklin Lakes, NJ) with
CELLQUEST software (BD Biosciences).
Bone-marrow DC isolation
The femurs and tibias of 6- to 8-week-old mice were
harvested and the bone marrow was flushed and dis-
rupted by pipetting with 2 ml RPMI-1640 using a syr-
inge with a 26-gauge needle. Cells were suspended and
passed through a cell strainer to remove small pieces of
bone and debris, and red blood cells were lysed with
ammonium chloride red blood cell lysis buffer (Sigma
Aldrich, St Louis, MO). Following washing, granulocytes,
B cells and red blood cell precursors were removed by
magnetic adsorption cell sorting (MACS; Miltenyi Bio-
tec, Auburn, CA) using a mAb cocktail of phyco-
erythrin-conjugated (PE-) anti-GR1, PE-anti-TER119,
PE-anti-B220/CD45R and anti-PE microbeads according
to the manufacturer’s instructions. Then, 5 · 105 cells/ml
were plated in 24-well plates (Nunc, Naperville, IL) in
1 ml of medium supplemented with 20 ng/ml recombi-
nant granulocyte–macrophage colony-stimulating factor
(rGM-CSF; BioSource, Camarillo, CA). The cultures
were fed every 2 days by gently swirling the plates, aspi-
rating 50% of the medium, and adding fresh medium
containing rGM-CSF.
DC harvesting and manipulation
Dendritic cells were harvested 6 days after bone-marrow
culture by removing Gr1+ granulocytes from cultures
using MACS with PE-anti-Gr1 mAb and anti-PE
microbeads. To induce maturation of DCs, 1 lg/ml
lipopolysaccharide (LPS; Salmonella Abortus Equi; Sigma-
Aldrich) was added to the cell culture for 18 hr before
harvest. To render DCs maturation-resistant, they were
fixed by resuspension in 2% (weight/volume) paraformal-
dehyde in Dulbecco’s modified Eagle’s minimum essential
medium (pH 80 buffer) for 10 min at 10, then washed
three times with Hanks’ buffered salt solution (HBSS)
buffer. Immature, fixed immature or fixed mature cells
were used for the following experiments.
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In vitro mixed lymphocyte reaction
T-cell-enriched single-cell suspensions were prepared
from the spleens of mice using a T-cell enrichment col-
umn (R&D Systems Inc, Minneapolis, MN) according to
the manufacturer’s instructions. Fixed or non-fixed,
immature or mature BM-derived DCs were cultured with
3 · 105 allogeneic T cells in 200 ll RPMI-1640 culture
medium containing 10% fetal bovine serum, 1% penicil-
lin/streptomycin and b2-mercaptoethanol in U-bottom
96-well plates. In experiments where whole splenocytes
were used, 5 · 105 cells were used as responders, or irra-
diated (25 Gy) allogeneic stimulators in the mixed lym-
phocyte reaction. After 3 days of culture, cells were
pulsed with [3H]thymidine (1 lCi per well, Amersham,
UK) for 16 hr. Cells were harvested using a multi-well
harvester and [3H]thymidine incorporation was deter-
mined using a liquid scintillation counter. Results are
expressed as the mean counts per minute ± standard
deviation (SD) from triplicate cultures. In some experi-
ments, T cells from TEa transgenic mice that were pre-
treated with FIDCs, were cultured for mixed lymphocyte
reaction and analysed for the changes in phenotype using
flow cytometry.
In vitro culture of CD4+ CD25+ T cells
Single-cell suspensions were prepared from lymph nodes of
naive CB6F1 mice and cells were stained with fluorescein
isothiocyanate (FITC)-conjugated anti-CD4 and PE-conju-
gated anti-CD25 (PharMingen). The CD4+ CD25) cells
and CD4+ CD25+ T cells were isolated by FACSAria (BD
Bioscience). The purity of the selected CD4+ CD25) cells
and CD4+ CD25+ T cells was greater than 98%. Immature
and mature DCs (5 · 104) were fixed with 2% paraformal-
dehyde and co-cultured with CD4+ CD25+ T cells
(5 · 105) for 96 hr in a 96-well U-bottom plate. [3H]Thy-
midine (1 lCi/well) was added for the last 16 hr. Plates
were harvested and [3H]thymidine incorporation was
evaluated in counts per minute (c.p.m.).
In vivo proliferation assay with CFSE staining
Single-cell suspensions of spleen and lymph nodes were
prepared from naı̈ve mice or allogeneic DC-pretreated mice
and labelled with a 5-carboxyfluorescein diacetate succin-
imidyl ester (CFSE; Molecular Probe, Inc. Portland, OR)
tracking fluorochrome as previously described.18 Allogeneic
mice were lethally irradiated (1000 rad) and subsequently
injected with 6 · 107 to 8 · 107 CFSE-labelled cells via the
tail vein. The mice were killed after 3 days, and spleen and
lymph node mononuclear cells were harvested and stained
with directly conjugated mouse monoclonal antibodies
against CD4, CD8 and H-2k. The adoptively transferred
cells were identified by gating H-2k+. The patterns of T-cell
proliferation were analysed as the intensity of CFSE. In
some experiments, CD4+ CD25+ T cells from C3H mice
that were pretreated with FIDCs, were depleted and the
purified CD4+ CD25) T cells were adoptively transferred
into the lethally irradiated host.
Islet transplantation
The transplantation of islet cells was performed on naı̈ve
or CB6F1 DC-pretreated C3H mice as previously
described.19 Briefly, CB6F1 donor pancreata were perfused
with 35 ml HBSS containing collagenase type IV 15 mg/
dl (Sigma-Aldrich) through the common bile duct and
incubated at 37 for 14 min. Islets were released from the
pancreata and purified in discontinuous Ficoll (Sigma-
Aldrich) gradients. The harvested islets were washed in
HBSS, and in excess of 600 islets were transplanted under
the renal capsule of each C3H recipient, which had been
rendered diabetic by a single intraperitoneal injection of
streptozotocin (250 mg/kg; Sigma-Aldrich). Allograft
function was monitored by serial blood glucose measure-
ments. Primary grafts were considered to be functional if
the blood glucose level was < 200 mg/dl 3 days after
transplantation. Grafts were considered to have been
rejected if two consecutive elevations in blood glucose
> 300 mg/dl occurred following a period of primary graft
function. In some recipients, CD4+ CD25+ T cells of C3H
recipients were depleted using a mAb (PC61) before and
after DC pre-treatment (days –1 and 3). To evaluate the
strain specificity, islets from CB6F1 (same as primary
graft) or from DBA1 (third-party graft; H-2q) mice were
grafted on the right kidney of the mice that had long-
term primary graft function.
Skin transplantation
Full-thickness tail skin from CB6F1 mice was grafted onto
the thoracic walls of naı̈ve or CB6F1 DC-pretreated C3H
recipients. Graft survival was monitored daily and was
considered to have been rejected if complete necrosis
occurred.
Localization of DCs
For the localization of infused DCs in secondary lym-
phoid organs, DCs stained with CFSE with/without fixa-
tion were introduced into mice via the tail vein. After 3
and 24 hr, the spleen was harvested and minced into a
single-cell suspension. CFSE+ cells were counted using a
flow cytometer.
Immunohistochemistry
Spleens were harvested from recipient mice at 3 hr after
adoptive transfer, embedded in OCT medium (Miles Inc.,
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Elkhart, IN), and frozen at 80. Frozen sections 6 lm
thick were fixed for 10 min in cold acetone. For immuno-
fluorescence analysis, the sections were stained overnight
at 4 with 2 lg/ml rat anti-mouse CD4 (R&D Systems
Inc.) for T cells and 2 lg/ml rat anti-mouse B220 (R&D
Systems Inc.) for B cells in blocking reagent. A second
layer of Alexa Fluor 488-conjugated anti-rat antibody
(Molecular Probes, Eugene, OR) was applied and incu-
bated at room temperature for 40 min. Primary anti-
bodies were omitted from sections used as negative
controls. Sections were evaluated blindly and randomly.
Incorporation of DCs labelled with CM-DiI (Molecular
Probes) and DAPI (Sigma Aldrich), was examined using
confocal laser-scanning microscopy (Carl Zeiss, Jena,
Germany) under · 200 magnification.
Statistical analysis
Statistical analyses were performed using chi-squared
tests, Kaplan–Meier cumulative plots and log-rank tests
where appropriate. P-values of < 005 were considered to
be statistically significant.
Results
The effect of fixation on BM-derived DCs.
Bone-marrow-derived DCs were harvested from CB6F1
mice and cultured in media which contained rmGM-CSF.
After 6 days of culture the majority (73–84%) of cells iso-
lated by negative selection using anti-Gr1 mAb micro-
beads were CD11c-positive DCs. In the absence of LPS
stimulation the expression of CD40, CD86 and major
histocompatibility complex (MHC) class II molecules on
harvested DCs was low (Fig. 1a) indicating that these
DCs were predominantly immature. Stimulation of the
immature DCs with LPS led to the increased expression
of CD40, CD86 and MHC class II (Fig. 1a) molecules,
which were indicative of maturation. Following cell sort-
ing and fixation of immature BM-derived DCs with 2%
paraformaldehyde, stimulation with LPS did not up-regu-
late the expression of CD40, CD86 or MHC II, indicating
that fixation rendered cells effectively resistant to changes
in maturity (Fig. 1a, middle column). Again, the matura-
tion phenotypes of DCs induced by LPS stimulation were
not changed with LPS re-stimulation when these DCs
were fixed with paraformaldehyde (Fig. 1a, right column).
To investigate whether fixation preserved the capacity of
DCs to stimulate allogeneic T-cell proliferation, immature
and mature CB6F1 (H-2b.d) BM-derived DCs were isolated
and fixed as described earlier. Following fixation, either
immature or mature cells were used to stimulate C3H
(H-2k) T cells in vitro. When DCs were co-cultured with
allogeneic T cells, fixed mature DCs (FMDCs) induced the
proliferation of allogeneic T cells at various DC : T-cell
ratios, although FMDCs were slightly less effective than
irradiated BM-derived DCs at inducing allogeneic T-cell
proliferation. This implies that paraformaldehyde fixation
does not abrogate the capacity of DCs to stimulate alloge-
neic T-cell proliferation when DCs were in a matured state.
Conversely, the proliferation of allogeneic T cells co-cul-
tured with FIDCs was minimal regardless of the DC : T-cell
ratio, implying that FIDCs are unable to stimulate alloge-
neic T-cell proliferation (Fig. 1b).
Effect of donor strain FIDC pre-treatment on
allogeneic T-cell responses
The absence of an allogeneic T-cell response to FIDCs
in vitro led us to hypothesize that FIDCs may be able to
suppress the allogeneic immune response in vivo. To test
our hypothesis, LPS-stimulated or non-stimulated BM-
derived DCs isolated from CB6F1 (H-2b.d) mice were fixed
(i.e. FMDCs or FIDCs), and were injected into naı̈ve C3H
(H-2k) mice (2 · 106 DCs per mouse) via the tail vein.
Immature, non-fixed DCs were also used for pre-treat-
ment as control. After 2 weeks, splenocytes were harvested
from DC-pretreated C3H mice or naı̈ve C3H mice and
labelled with CFSE before being injected into lethally irra-
diated CB6F1 hosts. To monitor the proliferation of T
cells, splenocytes were isolated from the CB6F1 hosts after
3 days. CD4+ T cells from naive C3H or immature, non-
fixed DC-pretreated C3H mice proliferated vigorously in
CB6F1 hosts in response to alloantigens, and a significant
proportion of cells underwent at least eight divisions.
CD4+ T cells harvested from C3H mice that had been pre-
treated with FMDCs 2 weeks earlier showed a similar pro-
liferation pattern to CD4+ T cells from naı̈ve C3H mice.
This implied that fixation of matured DCs did not destroy
the potential of T cells to proliferate in response to alloan-
tigen. Conversely, CD4+ T cells harvested from C3H mice
that had been pre-treated with FIDCs from CB6F1 mice
2 weeks earlier did not undergo more than two cell divi-
sions in irradiated CB6F1 mice. This implied that the allo-
geneic T-cell population was hyporesponsive to CB6F1
alloantigens (Fig. 2). However, T cells from C3H mice that
were pre-treated with FIDCs of DBA1 (H-2q) proliferated
in the irradiated CB6F1 host (as third-party control)
showing similar dynamics to the naı̈ve T cells (Fig. 2 last
row). We also evaluated the homeostatic proliferation of
CB6F1 T cells and confirmed the proliferation although it
was not as vigorous as the allogeneic response (fifth row).
CD8+ T cells showed a similar pattern of proliferation to
that observed with CD4+ T cells.
Donor strain FIDC pre-treatment and allograft
survival
The hyporesponsiveness of allogeneic T cells in response
to pre-treatment with FIDCs implied that donor strain
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FIDC pre-treatment may improve the long-term survival
of allogeneic grafts. To test this hypothesis, an MHC-mis-
matched islet and skin transplant model was utilized.
Immature or mature BM-derived DCs were harvested
from CB6F1 mice, fixed and injected into C3H recipients.
Some recipients were injected with unfixed immature
CB6F1 BM-derived DCs. After 14 days, the C3H mice
were grafted with CB6F1 islets after being rendered dia-
betic with streptozotocin. Pre-treatment with donor strain
FIDCs markedly prolonged islet allograft survival, and
some grafts survived for more than 100 days (Fig. 3),
whereas naı̈ve C3H mice rejected the islet allograft (mean
survival time; MST, 13 days, n = 4). Conversely, pretreat-
ment with donor strain FMDCs or unfixed immature
donor strain BM-derived DCs did not prolong islet allo-
graft survival (MST < 20 days) in both groups. Surgical
removal of the left kidney bearing the islet allograft was
performed after 120 days of engraftment. In the absence
of further immunosuppressive therapy, a second CB6F1
islet allograft was successfully engrafted without evidence
of rejection. In contrast, islet transplants from the third
party (DBA1; H-2q) were acutely rejected.
To confirm the increased allograft tolerance following
FIDC treatment in a more stringent model, skin grafts
from CB6F1 donors were transplanted onto C3H mice
that had been pre-treated with FIDCs from CB6F1 mice.
Long-term skin allograft survival of more than 120 days
MST was accomplished in five of nine recipients. The
untreated control C3H mice rejected the skin allograft
within 14 days (Fig. 4). Third-party skin grafts from
DBA1 (H-2q) mice onto C3H mice that had been pre-
treated with CB6F1 FIDCs were rejected within a time-
frame similar to that for grafts transplanted onto naı̈ve
mice. This implied that donor strain FIDC-induced hypo-
responsiveness to allografts was alloantigen-specific.
Distribution of transferred BM-derived DCs
Dendritic cells are known to interact and present antigens
to T cells in lymphoid organs. To test whether fixed
BM-derived DCs could localize to lymphoid organs and
interact with alloreactive T cells, CFSE labelled FIDCs,
non-fixed CFSE-labelled DCs, or phosphate-buffered sal-
ine controls were injected into C3H mice. After 3 hr,
Figure 1. Fixed dendritic cells (DCs) remain
biologically effective. Bone-marrow (BM)-
derived DCs harvested from CB6F1 mice were
used to analyse cell surface molecules (a) or to
stimulate allogeneic T cells for proliferation
(b). (a) Expressions for I-Ab (major histocom-
patibility complex class II; MHC-II), CD86
and CD40 were assayed using BM-derived
DCs. When BM-derived immature DCs were
stimulated with lipopolysaccharide (LPS; left
column, thick line), the expression of all three
markers increased significantly, compared with
non-stimulated BM-derived DCs (left column,
thin line). However, after fixation, LPS stimu-
lation did not enhance the expression of these
costimulatory molecules or MHC II molecules
on BM-derived DCs (middle column). When
BM-derived DCs were matured and fixed, re-
stimulation with LPS did not change the
expressions of these molecules (right column).
(b) Different numbers of irradiated DCs (tri-
angular dot), fixed mature DCs (FMDCs;
square dot) and fixed immature DCs (FIDCs;
round dot) from CB6F1 mice were co-cultured
with allogeneic C3H T cells. FIDCs did not
induce the proliferation of C3H T cells, while
FMDCs retained the stimulatory effect on allo-
geneic C3H T cells comparable to irradiated
DCs. T cells were cultured for 96 hr and
[3H]thymidine (1 lCi/well) was added for the
last 16 hr.
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spleens were harvested, and analysed by flow cytometry.
As expected, CFSE+ cells were detectable outside the lym-
phocyte fraction by flow cytometric analysis. Splenocytes
harvested from mice that were injected with non-fixed
immature CB6F1 BM-derived DCs comprised 12%
CFSE+ cells, and splenocytes harvested from mice injected
with FIDCs comprised 06% CFSE+ cells (Fig. 5a). At
24 hr after DC injection, CFSE fluorescence was detected
in 044% of non-fixed DC-treated splenocytes and 043%
of fixed DC-treated splenocytes. Immunohistochemical
localization of infused DCs was performed using confocal
microscopy. CM-DiI labelled DCs were detectable along
with T and B cells in the spleen irrespective of prior fixa-
tion (Fig. 5b). These DiI+ DCs were nucleated intact cells
as confirmed by DAPI positivity (Fig. 5b third row).
The association of CD4+ CD25+ T cells for
hyporesponsiveness after FIDC pretreatment
Investigators have recently begun to elucidate the role of
DCs in the active regulation of the immune response,
particularly with regard to CD4+ CD25+ regulatory T
cells. We hypothesized that donor strain FIDC pre-treat-
ment abrogated the allogeneic T-cell response via CD4+
CD25+ regulatory T cells. To test our hypothesis, we har-
vested splenocytes from C3H mice that had been pre-
treated with FIDCs from CB6F1 mice and depleted the
population of CD25+ cells using MACS with a biotin-
conjugated anti-CD25 mAb and streptavidin beads. The
Figure 2. Fixed immature dendritic cell
(FIDC) pre-treatment suppressed alloreactive
T-cell proliferation in vivo. Splenocytes were
recovered from naı̈ve C3H, CB6F1 fixed
mature dendritic cell (FMDC)-prereated C3H
mice, CB6F1 FIDC-pretreated C3H mice and
DBA1 FIDC-pretreated C3H mice and labelled
with 5-carboxyfluorescein diacetate succinim-
idyl ester (CFSE). These cells were adoptively
transferred into lethally irradiated CB6F1 hosts
and then allowed to proliferate. T cells from
CB6F1 FIDC pre-treated C3H did not prolifer-
ate in CB6F1 hosts, while T cells from naı̈ve
and CB6F1 FMDC-pretreated mice showed
significant proliferation. FIDC from third-party
donor (DBA1; H-2q) was not effective to show
hyporesponsiveness of T cells against allogeneic
antigens (fifth row). Homeostatic proliferation
of T cells from CB6F1 was evaluated as control
(fourth row).
Figure 3. Donor strain fixed immature dendritic cell (FIDC) pre-
treatment prolonged islet allograft survival. Bone marrow (BM)-
derived DCs were prepared from CB6F1 mice and transplanted into
C3H recipients with or without stimulation and/or fixation. After
2 weeks, CB6F1 islets were transplanted into diabetic C3H recipients.
While naı̈ve C3H recipients (filled dot), C3H hosts pre-treated with
immature unfixed CB6F1 BM-derived DCs (filled square) and C3H
hosts pre-treated with fixed mature dendritic cells (FMDCs; empty
square) rejected the islet allografts within 20 days, the C3H recipients
pre-treated with CB6F1 FIDC (three out of five recipients) showed a
significantly prolonged allograft survival. This is one of two indepen-
dent transplantation experiments and the other experiments showed
the same result.
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CD25-depleted cells were labelled with CFSE and injected
into irradiated CB6F1 mice. The proliferation pattern of
the FIDC-pre-treated, CD25-depleted C3H T cells was
similar to that of naı̈ve C3H T cells, implying that FIDC-
induced hyporesponsiveness was mediated, at least in
part, by CD25+ regulatory T cells (Fig. 6a). Similar proli-
feration patterns were observed in other experiments with
C3H mice that had been depleted of CD25+ T cells using
an in vivo anti-CD25 antibody before DC introduction.
These mice had been injected with FIDCs from CB6F1
mice, and splenocytes harvested after 2 weeks to analyse
CFSE-stained C3H T-cell proliferation in lethally irradi-
ated CB6F1 mice (data not shown). The association of
CD4+ CD25+ regulatory T cells in FIDC-induced hypo-
responsiveness was further probed using in vitro prolifera-
tion capacity. When CD4+ CD25+ regulatory T cells
(C3H) were isolated and co-cultured with immature DCs
(CB6F1), there was obvious clonal expansion of regula-
tory T cells. However, fixed DCs did not induce the
proliferation of CD4+ CD25+ regulatory T cells during
4 days of co-culture (Fig. 6b). To evaluate the effect of
CD4+ CD25+ regulatory T cells on graft survival, we
depleted these cells of C3H recipients using mAbs before
the FIDC pre-treatment. As shown in Fig. 6(c), the dia-
betic recipients that were depleted of CD4+ CD25+ T cells
at days – 1 and 3 of FIDC pre-treatment, rejected the islet
graft promptly, but the presence of CD4+ CD25+ T cells
at the time of DC pre-treatment was effective in main-
taining the allogeneic graft.
To evaluate the effects of incomplete antigen presenta-
tion on the responding T-cell clones, we analysed the
activation status of T cells using in vitro mixed lympho-
cyte reaction. The FIDCs from CB6F1 mice were injected
into TEa transgenic mice. CD4+ T cells from Tea trans-
genic mice express a TCR that recognizes the peptide
ASFEAQGALANIAVDKA in the context of I-Ab (peptide
corresponds to positions 52 to 68 from the a-chain of I-E
class II molecules).17 After 2 weeks, purified T cells were
cultured with irradiated splenocytes from CB6F1 mice.
CD4+ T cells from TEa transgenic mice that had been
pre-treated with FIDCs from CB6F1 mice showed a sig-
nificant decrease in proliferation (65% reduced at 5 days
of culture, P < 005; Fig. 6d), and retained the expression
of CD62L (Fig. 6e). CD4+ T cells taken from naive TEa
transgenic mice readily responded to the cognate antigen
and showed down-regulation of CD62L expression. To
assess the relationship between hyporesponsiveness
induced by FIDC pre-treatment and cellular apoptosis,
T-cell apoptosis was evaluated by Annexin-V staining.
Although the rate of apoptosis varied between experi-
ments, the number of Annexin-V-positive T cells was
consistently less in co-cultured systems when T cells from
pre-treated transgenic mice were primed with FIDCs
(Fig. 6f) than when T cells from naı̈ve transgenic mice
were used.
Discussion
In this study we examined the allogeneic immune
response of recipients following pre-treatment with
donor-strain-derived FIDCs. Since the immaturity of DCs
is important for the maintenance of self tolerance,5 many
investigators have tried to enhance allograft tolerance
using immature DCs.4,6,20–22 However, previous attempts
have not shown consistent results, possibly because the
immature DCs mature spontaneously following the
in vivo state and so can activate the immune response.12
To overcome the plasticity associated with the DC pheno-
type, we treated cells with paraformaldehyde to render
them unable to mature. We used 2% paraformaldehyde
as the fixative agent in our experiments because lower
concentrations can be ineffective.15 Previous studies have
used rGM-CSF at low concentrations in culture,23 or
blocking nuclear factor-jB oligodeoxyribonucleotide24 to
prevent DC maturation. Both of these studies produced
excellent results, but demonstrated limitations because of
the low number of DCs used, and activation of the
nuclear factor-jB-independent pathway of DC stimula-
tion. In our study, we were able to obtain sufficient num-
bers of DCs from donor bone marrow, as previously
described.20 The fixation of cell membranes rendered the
cells incapable of up-regulating surface proteins, including
costimulatory molecules, irrespective of the activation
signals or pathways involved (Fig. 1).
One particular concern regarding this approach was
that fixation might have destroyed the ability of DCs to
function as APCs, thereby abrogating their ability to stim-
ulate allogeneic T cells to proliferate. However, fixation
did not eliminate the potential for allogeneic T-cell prolif-
eration (Fig. 1b). When mature DCs were fixed and used
Figure 4. Fixed immature dendritic cell (FIDC) pre-treatment pro-
longed skin allograft survival in a donor-specific manner. C3H recip-
ients pretreated with CB6F1 FIDCs were grafted with skin from
CB6F1 or DBA1 mice. Skin grafts from CB6F1 mice showed rejec-
tion-resistance (open circle, five out of nine recipients), while the
recipients rejected the third-party skin grafts promptly (open square,
i.e. DBA1; H-2q) irrespective of pre-treatment as non-treated con-
trols (filled circle). This is one of two independent transplantation
experiments and the other experiment showed similar result.
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for allogeneic stimulation, T cells actively proliferated,
although the magnitude of proliferation was less than the
magnitude observed using irradiated DCs. This finding
suggests that fixed cell surface proteins are able to present
antigens to T cells, and that the maturation status of DCs
was the crucial factor for the induction of an immune
response. Yamazaki et al. demonstrated that fixed DCs
could stimulate the proliferation of T cells using in vitro
culture systems, although unfixed cells were more effec-
tive in activating T-cell expansion.25 Although the results
of chemical fixation of APCs on the allogeneic immune
response are conflicting, the determining factors that lead
fixed APCs to be stimulatory or inhibitory were shown to
be the cell types used and the membrane properties at the
time of fixation.14–16
The observation of in vitro hyporesponsiveness of allo-
geneic T cells to FIDCs encourages us to investigate this
phenomenon using an in vivo allogeneic immune
response model. By monitoring T cells in irradiated
donor hosts using CFSE fluorescence, it was revealed that
FIDC pre-treatment abrogated donor-antigen-induced T-
cell proliferation (Fig. 2). Consistent with these results,
the pre-treatment of recipients with donor-strain FIDCs
enabled the prolonged survival of engrafted skin and islet
cells (Figs 3, 4). The immunomodulatory effect of FIDCs
was also donor specific; third-party grafts were rejected
within a similar time-frame to grafts rejected by naı̈ve
recipients. These data suggest that pretreatment of
recipients with fixed DCs did not render hosts immuno-
compromised, instead it induced antigen-specific hypore-
sponsiveness presented by the immature DCs. The finding
that claimed that fixed DCs were able to reach the spleen
after in vivo transfer (Fig. 5) also supported our hypothe-
sis. Dendritic cells are expected to interact with T cells in
secondary lymphoid organs to direct the immune
response against antigens. We confirmed that the intro-
duced DCs reached lymphoid organs in intact-cell state
because CM-DiI+ cells were also DAPI+ (Fig. 5b). To
induce the full activation of the immune response, a per-
iod of around 24–48 hr of DC–T-cell interaction is
required, however, for aborted activation of cognate T
cells the duration of the DC–T-cell interaction appears to
be shorter.26,27 We demonstrated that FIDCs were present
in the spleen following intravenous injection for at least
24 hr as reported previously.23,24 We therefore speculate
that the introduced FIDCs remain in secondary lymphoid
organs long enough to elicit a DC–T-cell interaction, or
suppression of the immune response.
Figure 5. Transplanted, fixed dendritic cells
(DCs) were incorporated into host spleen. (a)
Three hours after injection with 5-carboxyfluo-
rescein diacetate succinimidyl ester (CFSE)-
labelled fresh or fixed DCs, the presence of
transplanted DCs in spleens was analysed.
Control mice were injected with phosphate-
buffered saline. CFSE intensity was analysed by
fluorescence-activated cell sorter; 06–12% of
splenocytes were CFSE positive. (b) Cryosec-
tioned spleen tissue was examined by confocal
microscopy (original magnification · 200).
CM-DiI labelled DCs and Alexa Fluor 488-
conjugated antibody labelled T or B cells were
traced. Labelled DCs were nucleated cells as
confirmed by DAPI staining.
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The precise mechanisms of the induction of donor-spe-
cific tolerance using DC transplantation remain to be elu-
cidated.28,29 Dendritic cells have been shown to play a
role in the deletion of alloreactive T cells.30,31 Considering
the remarkably high frequency of alloreactive T cells, it
seems possible that deletion mechanisms play a key role
in the induction of tolerance to MHC-mismatched
allografts.32–35 In addition, recent investigations have
revealed that DCs are involved in the expansion of immu-
noregulatory T cells such as CD4+ CD25+ T cells, which
are currently being intensely investigated for their role in
the active regulation of both self and allograft toler-
ance.9,36,37 These findings suggest that DCs have the
potential to regulate the immune response via effector T
Figure 6. T-cell hyporesponsiveness induced by fixed immature dendritic cells (FIDCs) is dependent upon CD4+ CD25+ regulatory T cells and
shows clonal hyporeactivity. (a) Splenocytes were harvested from C3H mice pretreated with CB6F1 FIDC and CD4+ CD25+ cells were shown to
be depleted. The proliferation pattern of CB6F1 FIDC pre-treated, CD25+ cell depleted C3H T cells was similar to that of naı̈ve C3H T cells. (b)
CD4+ CD25+ T cells from C3H mice were stimulated by either un-fixed or fixed dendritic cells from CB6F1 mice. Allogeneic DCs induced prolif-
eration of CD4+ CD25+ T cells but fixed DCs did not induce cell proliferation in 4 days of culture system. T cells were cultured for 96 hr and
[3H]thymidine (1 lCi/well) was added for the last 16 hr. (c) The recipients whose CD4+ CD25+ T cells were depleted at the time of FIDC
pre-treatment rejected the graft promptly, whereas the recipients with intact CD4+ CD25+ T cells during FIDC pre-treatment retained the graft
successfully (n = 4, each group). (d) CD4+ T cells from TEa transgenic mice that had been pre-treated with FIDCs from CB6F1 mice showed a
significant decrease in proliferation upon cognate antigen priming, while CD4+ T cells from naı̈ve TEa transgenic mice proliferated actively. (e)
CD4+ T cells from TEa transgenic mice that had been pre-treated with FIDCs from CB6F1 mice retained the expression of CD62L in significant
portions of Vb6 T cells, but T cells from naı̈ve Tea transgenic mice were activated after cognate antigen priming. (f) When T cells from pre-
treated transgenic mice were primed with FIDCs, the number of annexin-V+ cells was less than in the co-cultured system with T cells from
naı̈ve transgenic mice.
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cells and/or regulatory T cells, and reinforce trials
expanding regulatory T cells.38 Our study focused on the
role of CD4+ CD25+ regulatory T cells in the immuno-
modulatory effects of fixed immature DCs. In the absence
of CD25+ T cells the immunomodulatory effect of FIDC
pre-treatment was abolished, exemplifying the importance
of CD25+ regulatory T cells in mediating the immuno-
modulatory effect of FIDCs (Fig. 6). The hyporesponsive-
ness of T cells can be explained by the nature of anergic
T cells, which is characterized by inefficient T-cell activa-
tion.39 Our qualitative study clearly demonstrates that the
exposure of functional cognate antigens to T cells is criti-
cal for the induction of T-cell activation (Fig. 6).
This study has demonstrated that fixed immature
donor-derived DCs can be used to induce donor-specific
immune modulation in transplant recipients, thereby
revealing their potential use in transplantation medicine.
As the mechanisms underlying the effects of donor-
derived DC pre-treatment are elucidated, their clinical
application may provide a dependable therapeutic modal-
ity.
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